Brian Mann Earlier this year, Naida Rutherford, the coroner in Richland County, South Carolina, was helping investigate what appeared to be a mysterious overdose. The case had many of the hallmarks of a typical fentanyl death. "Every sort of physical manifestation, like the foam coming from the mouth and nose, as if they had an overdose," Rutherford said. "Their blood tested negative for any substance, which was very odd." Her team was stumped, so Rutherford expanded the testing, looking for new compounds. "That's where we found the cychlorphine," she told NPR, referring to one of the incredibly potent synthetic opioids spreading fast in the U.S. street drug supply. Sponsor Message The state of Virginia has seen drug overdose deaths plunge by more than 40% in a single year. Many other states are seeing improvements above 30%. Why is this happening? Researchers say it may be a combination of factors, some hopeful and some painful. "This is the first time we've seen it in South Carolina, which is very scary because none of us knew to test for it." Experts say the U.S. addiction crisis is evolving fast, in ways that appear both hopeful and incredibly dangerous. The peril comes from a street drug supply that chemists now describe as a "synthetic soup." Where once most drug users mostly consumed plant-based substances such as cocaine and heroin, drug gangs and cartels have shifted to producing and selling synthetic substances made from industrial chemicals. © 2026 npr

Keyword: Drug Abuse
Link ID: 30199 - Posted: 04.15.2026

By Jonathan Corum and Matt Richtel Illicit labs are creating new synthetic drugs at breakneck speed. Dangerous, untested compounds are reaching users long before health agencies know they exist. Older drugs are regularly modified to create novel threats. Ecstasy is a prime example. The party drug MDMA has been illegal since 1985. Its molecular structure can be drawn like this: But what if you could add one atom to this molecule to change both the experience of taking the drug and its legal status? You can. A single oxygen atom changes the molecule to methylone, which provides an Ecstasy-like euphoria. The discovery of what this simple change could do has had a profound consequence. When methylone reached the U.S. market in 2010 the drug could be sold legally in corner stores and smoke shops as “bath salts.” But methylone wasn’t the end of the story. Illicit chemists now use methylone’s structure as a template for modern-day alchemy. New drug laws push them to invent new variants, which emerge in the illicit drug market with untested potencies and effects — a vicious cycle that has been impossible to contain. These chemists are located in unregulated labs around the globe, from big enterprises in China and India that produce drugs and their precursor compounds in huge volumes, to single-person and small domestic operations that cut and package drugs for retail sale. Some of the most-used drugs, such as fentanyl, are mixed in Mexico and exported north. © 2026 The New York Times Company

Keyword: Drug Abuse
Link ID: 30197 - Posted: 04.11.2026

By Andrew Jacobs As researchers have sought to demonstrate the therapeutic benefits of mind-altering drugs like LSD and psilocybin “magic mushrooms,” many have struggled to explain exactly how these compounds work on the human brain. One way scientists have tried to show what these compounds do is by using functional M.R.I. machines to peer into the brains of research participants in the midst of a psychedelic experience. This has produced evocative color images that show a maelstrom of activity as the drugs disrupt patterns of connectivity between brain regions and networks. But the interpretations of those scans, published in scientific journals, have been inconsistent and even contradictory. Over the past five years, an international consortium of researchers has tried to make sense of the divergent results by bringing together the data from nearly a dozen brain imaging studies in five countries that have been published since 2012. The studies included more than 500 scans of 267 research participants on five substances: LSD, psilocybin, mescaline, DMT and ayahuasca. Their findings, published on Monday in the journal Nature Medicine, suggest that psychedelics prompt a welter of activity between regions of the brain that normally operate somewhat independently: the areas that process sensory information like vision, hearing and touch, and those involved with abstract thinking and self-reflection. The research suggests that psychedelic compounds temporarily reduce the separation between how we think and how we perceive, which could explain the neurological mechanics behind the sensory distortions, mystical experiences and ego dissolution that patients report during sessions. © 2026 The New York Times Company

Keyword: Drug Abuse; Consciousness
Link ID: 30193 - Posted: 04.08.2026

By Catherine Offord For most people, Oktoberfest means guzzling liters of beer inside a giant tent. But for one research group in Denmark, it’s a chance to study how our bodies know when we’ve had enough. In a preprint posted on bioRxiv last week, researchers combined a small study of people at Germany’s fall beer festival with mouse experiments, genetic analyses, and blood tests from drunk medical students as well as people with alcohol dependence. Their findings, though preliminary, hint that a hormone commonly associated with morning sickness might also have a role in limiting humans’ alcohol consumption. “I found it fascinating,” says Marlena Fejzo, a women’s health scientist at the University of Southern California who has studied GDF15, the hormone involved. Though the study relies mostly on associations and can’t prove cause and effect, it “lends support” to the idea that GDF15 stops us from overconsuming harmful substances, she adds. GDF15 rises sharply during early pregnancy and is thought to contribute to vomiting and feelings of sickness. Some researchers think it evolved as a protective mechanism: Nausea may help an expectant parent avoid unfamiliar or spoiled food that could harm the fetus. But GDF15 is also present in people who aren’t pregnant and has been linked to appetite suppression. It has even attracted interest from the pharmaceutical industry as a potential antiobesity drug. Matthew Gillum, an endocrinologist at the University of Copenhagen, began to wonder about the hormone’s effect on alcohol intake after collaborating on a study of revelers at the Roskilde music festival. That research measured blood hormone levels in young men who’d spent a week binge drinking and eating junk food and found multiple changes—including a rise in GDF15. © 2026 American Association for the Advancement of Science.

Keyword: Sexual Behavior; Hormones & Behavior
Link ID: 30168 - Posted: 03.21.2026

Mariana Lenharo The weight-loss drugs that took the world by storm a few years ago have a drawback for anyone afraid of needles: they must be injected weekly. But scientists have been racing to perfect anti-obesity pills — which are now coming to market. An oral anti-obesity drug called orforglipron is likely to be approved by US regulators by the end of April, pharmaceutical analysts say. In December, a pill version of the obesity drug semaglutide won US regulatory approval. Both drugs belong to the class of therapies called glucagon-like peptide-1 (GLP-1) receptor agonists. Semaglutide, sold as Wegovy, is made by Novo Nordisk in Bagsværd, Denmark; orforglipron is made by Eli Lilly and Company in Indianapolis, Indiana. Clinical-trial results have been positive. After around one year of treatment at the highest dosage, people taking orforglipron lost, on average, about 11% of their body weight1, and those taking semaglutide pills lost almost 14%2. But it’s uncertain whether pills could one day replace the GLP-1 pens that have become a weight-loss staple. Oral drugs face formidable developmental challenges, and several injected drugs cause greater weight loss than does either orforglipron or oral semaglutide: the approved injectable drug Zepbound, for example, leads to weight loss of up to 21% of body weight3. “It’s encouraging, and it’s fantastic to have double-digit weight loss with a pill,” says Daniel Drucker, an endocrinologist at the University of Toronto in Canada. “But so far, rather than replace, I would say they’re going to complement the options that we have.” There’s a good reason why the original GLP-1 receptor agonists, which mimic the natural hormone glucagon-like peptide-1, were sold in injectable form. The drugs are composed of peptides, which are relatively large molecules. Because of their size, digestive enzymes quickly break them down, and the intestinal lining limits their entry into the bloodstream. © 2026 Springer Nature Limited

Keyword: Obesity
Link ID: 30163 - Posted: 03.19.2026

By Robert Draper The hallucinations began the moment I lay back onto the mat and pulled the mask over my eyes. Oh, I instantly thought, this is not at all what I expected. The first images were assembled like a film strip, a sharply focused Technicolor row of strong, grim-faced men who appeared to be some sort of tribal chiefs. Within seconds, a green tint covered their faces, which then dissolved, replaced by images of conflict. Bodies strewed across a battlefield. Starving children. They, too, dissolved. A pile of rocks took shape. From the pile, several long, dark snakes slithered out. This could be unpleasant, I thought. A crackling sensation coursed through my entire body, as if all my neurons were firing — not in any way painful, but also inescapable. I could feel my hands sweating. My ears buzzed, and it wasn’t long before I heard the murmuring voices of people who weren’t there, followed by the sound of puking from people who were. There were 11 of us in the treatment room, in a basement in a cottage that overlooked the Pacific Ocean just south of Tijuana, Mexico, where ibogaine — a Schedule I drug in the United States — is legal. It was the night before Thanksgiving. We all had our reasons for coming to the treatment clinic called Ambio Life Sciences. Several in the group were veterans suffering from PTSD, traumatic brain injury, substance abuse or some combination of those. A sex-crimes detective had been in a terrible car accident and lost much of her short-term memory. A Marine veteran and blueberry farmer in Georgia was quietly drinking his life away. And there was Erin, a Texas-based corporate consultant who had suffered trauma that began in childhood and continued in the workplace. Erin’s mat was next to mine at the far end of the treatment room. Because we were the only two in the group not to throw up during the 10-hour experience, we later referred to ours as the Quiet Corner. The drug is derived from the Tabernanthe iboga plant, found mainly in Gabon in central Africa. The powerful hallucinogen has long been used there in the initiation ritual that is part of the Bwiti spiritual tradition, involving an intense all-night group ceremony of dance and music and fire-keeping that culminates in a trancelike state. © 2026 The New York Times Company

Keyword: Stress; Drug Abuse
Link ID: 30156 - Posted: 03.11.2026

Will Stone The long-running campaign against smoking could find reinforcements from the new wave of research into psychedelics. Though much of the attention around psychedelics has focused on depression and other mental health conditions, researchers believe these substances also hold the potential to transform addiction treatment. A new study makes the strongest case yet for a psychedelic drug's impact on smoking, which remains the leading cause of preventable death in the U.S. The trial, conducted by a team at Johns Hopkins University, compared nicotine patches to the active ingredient in magic mushrooms, known as psilocybin. At the end of six months, those who had taken just one dose of psilocybin had more than six times greater odds of being abstinent from cigarettes than their counterparts who relied on the nicotine substitute. Everyone in the study also underwent cognitive behavioral therapy for smoking cessation over the course of 13 weeks. "I was surprised by the sheer magnitude of the effect," says Matthew Johnson, the study's author and a professor of psychiatry at Johns Hopkins. The findings, published in the medical journal JAMA Network Open on Tuesday, came from a sample of 82 current smokers, who were randomly separated into two groups. Similar to other psychedelic trials, the participants had support from facilitators to make sure they were comfortable and prepared for their trip. They ingested a relatively high dose of pure psilocybin. © 2026 npr

Keyword: Drug Abuse
Link ID: 30155 - Posted: 03.11.2026

Denis Campbell Weight loss drugs could help people avoid getting addicted to alcohol, tobacco and drugs such as cannabis and cocaine, a study has found. They could also reduce the risk of people already addicted to illicit substances having an overdose, ending up in hospital or dying, according to research published in the British Medical Journal. Glucagon-like peptide-1 receptor agonists used to treat type 2 diabetes and obesity, such as Mounjaro and Ozempic, are thought to work by influencing the brain’s reward pathways in order to cut cravings. They help people feel fuller by mimicking the natural substance released after eating. The US study analysed 606,434 US veterans with type 2 diabetes, who were monitored for up to three years. It found that GLP-1s reduced the risk of alcohol-related disorders in those with no history of substance use by 18% and of using cannabis (14%), cocaine (20%), nicotine (20%) and opioids (25%), compared with those on other sodium-glucose cotransporter-2 drugs also used to treat diabetes. Weight loss drugs also reduce the risk of people already using substances from overdosing (39%), needing emergency help in A&E (31%) or dying (50%). “This study adds to emerging research exploring whether GLP-1 medicines may influence brain pathways involved in reward and addiction”, said Prof Claire Anderson, the president of the Royal Pharmaceutical Society, which represents 35,500 UK pharmacists. She added: “As this was an observational study, it is important to be clear that it does not show these medicines prevent or treat addiction. Further research, including clinical trials, will be needed to understand whether GLP-1 medicines have a direct effect.” © 2026 Guardian News & Media Limited

Keyword: Drug Abuse; Obesity
Link ID: 30150 - Posted: 03.07.2026

By Nick Hilden Since the start of the so-called psychedelic renaissance some 25 years ago, writers have tackled the subject from the vantages of science, politics, mental health, productivity, creativity, spirituality, how-to, and even cooking. With his new book On Drugs, Justin Smith-Ruiu explores these powerful drugs through a philosophical lens, analyzing their effects and implications via thinkers spanning Foucault to Freud, Spinoza to Sartre, and scores of others who over the past 2,000 years have sought to explain the mysteries of the human experience. While authors have applied philosophy to psychedelics before, they have typically done so through the framework of mental health or otherwise medicinal frameworks, while Smith-Ruiu is more interested in treating psychedelics as philosophical objects worthy of examination in and of themselves. At the same time, he follows the drugs down the rabbit hole, sizing up what psychedelics taught him on a personal level, and delving into questions surrounding the scientific prohibition of auto-experimentation, whether the hallucinations conjured by psychedelics are real or imagined, and what they have to teach us about the nature of reality. A professor of history and science, Smith-Ruiu has previously applied philosophical analysis to some of the most pressing issues of our day. In The Internet Is Not What You Think It Is, he explored how the internet arose from some of our deepest philosophical yearnings. In Irrationality, he asserted that human irritation is fundamental to the human experience rather than a contextual social aberration. And in Nature, Human Nature, and Human Difference, he argued that our contemporary conceptions of race are not innate but rather emerged from the modern scientific efforts to classify and systematize. (He also happens to have an asteroid named after him—it doesn’t get much “higher” than that.) © 2026 NautilusNext Inc.,

Keyword: Drug Abuse; Consciousness
Link ID: 30146 - Posted: 03.04.2026

Ian Sample Science editor People with major depressive disorder can see a rapid and lasting improvement after a single dose of the psychedelic drug dimethyltryptamine (DMT) when it is combined with psychotherapy, doctors have said. A small clinical trial involving 34 people found that psychedelic-assisted therapy prompted a swift reduction in depressive symptoms that endured long after the drug had worn off, with some still feeling the benefits six months later. “There is an immediate antidepressant effect that is significantly sustained over a three-month period and that’s exciting because this is one session with a drug, embedded in psychological support,” said Dr David Erritzoe, a psychiatrist at Imperial College London and lead investigator on the trial. Although preliminary, the results add to a growing body of evidence that psychedelic drugs, when coupled with psychotherapy, could help to alleviate depression in the millions of people worldwide who do not respond to existing antidepressants or therapies. An estimated 100 million people worldwide have treatment-resistant depression, defined as a major depressive disorder that has not responded to at least two antidepressants. About half are unable to perform routine daily tasks. The trial, reported in Nature Medicine, focused on people with moderate to severe treatment-resistant depression. One half received a single 21.5mg dose of DMT infused into a vein over 10 minutes. The other half received a placebo infused the same way. All of the participants had psychotherapy and follow-up assessments. © 2026 Guardian News & Media Limited

Keyword: Depression; Drug Abuse
Link ID: 30126 - Posted: 02.18.2026

Ian Sample Science editor People who have a couple of teas or coffees a day have a lower risk of dementia and marginally better cognitive performance than those who avoid the drinks, researchers say. Health records for more than 130,000 people showed that over 40 years, those who routinely drank two to three cups of caffeinated coffee or one to two cups of caffeinated tea daily had a 15-20% lower risk of dementia than those who went without. The caffeinated coffee drinkers also reported slightly less cognitive decline than those who opted for decaf and performed better on some objective tests of brain function, according to a report published in the Journal of the American Medical Association. The findings suggest habitual tea and coffee drinking is good for the brain, but the research cannot prove it, as caffeine drinkers may be less prone to dementia for other reasons. A similar link would arise if poor sleepers, who appear to have a greater risk of cognitive decline, steered clear of caffeine to get a better night’s rest. “Our study alone can’t prove causality, but to our knowledge, it is the best evidence to date looking at coffee and tea intake and cognitive health, and it is consistent with plausible biology,” said the lead author, Yu Zhang, who studies nutritional epidemiology at Harvard University. Coffee and tea contain caffeine and polyphenols that may protect against brain ageing by improving vascular health and reducing inflammation and oxidative stress, where harmful atoms and molecules called free radicals damage cells and tissues. Substances in the drinks could also work by improving metabolic health. Caffeine, for example, is linked to lower rates of type 2 diabetes, a known risk factor for dementia. © 2026 Guardian News & Media Limited

Keyword: Drug Abuse; Alzheimers
Link ID: 30113 - Posted: 02.11.2026

By Ellen Barry A new analysis of birth cohorts in the Canadian province of Ontario has found a striking rise in the incidence of psychotic disorders among young people, a finding that its authors said could reflect teens’ increasing use of substances like cannabis, stimulants and hallucinogens. The study, published on Monday in The Canadian Medical Association Journal, found that the rate of new diagnoses of psychotic disorders among people ages 14 to 20 increased by 60 percent between 1997 and 2023, while new diagnoses at older ages plateaued or declined. Compared with people born in the late 1970s, those born in the early 2000s were about twice as likely to have been diagnosed with a psychotic disorder by age 20. The researchers included 12 million people born in Ontario between 1960 and 2009, of which 0.9 percent were diagnosed with a psychotic disorder during the study period. The study was epidemiological and did not try to identify a cause for the rising prevalence. There are a number of possible explanations, among them older paternal age, the stress of migration, neonatal health problems and early intervention programs that now regularly identify the disorders at younger ages, the authors note. But Dr. Daniel Myran, one of the study’s authors, said he undertook the study, in part, to follow up on concerns that the legalization of cannabis might increase population-level rates of schizophrenia and other psychotic disorders. “I was expecting to see some increases in these younger folks, but I was quite surprised by the scale,” said Dr. Myran, a family physician and research chair at North York General Hospital. He said the results suggested a need for more research into the impact of expanding cannabis use by young people. © 2026 The New York Times Company

Keyword: Schizophrenia; Drug Abuse
Link ID: 30106 - Posted: 02.04.2026

By Amy X. Wang Alice, fumbling through Wonderland, comes across a mushroom. One bite of it shrinks her down in size. Chowing on the other side makes her swell up, huge, taller than the treetops. Urgently, Alice sets to work “nibbling first at one and then at the other, and growing sometimes taller and sometimes shorter,” until finally she succeeds in “bringing herself down to her usual height” — whereupon everything feels “quite strange.” Is this Lewis Carroll’s 1865 fantasy tale or … the average body-conscious, improvement-obsessed 2026 Whole Foods shopper? Mushrooms, long venerated in literature as dark transformative forces, have become Goopified. Nowadays, you can chug “adaptogenic mushroom coffee,” slurp “functional mushroom cocoa,” doze off with “mushroom sleep drops” or ingest/imbibe any number of other tinctures in the billion-dollar fungal supplements market that promise to fine-tune, or even totally recalibrate, the self. The latest and hottest items in this booming new retail category are mushroom gummies, gushed over by wellness influencers, spilling out from supermarket shelves right there next to your standard cough drops and protein bars. Fungi have aided medical advances like antibiotics and statins, it’s true, and certain species have shown promising results in fighting Parkinson’s or cancer — but what these pastel gumdrops proffer is a broader, more elliptical “cellular well-being.” The mystique feels intentional on product-makers’ part: Like Carroll’s baffled heroine, maybe you’re meant to be in a bit of thrall to the mysterious, almighty mushroom — lurching through Wonderland, charmed and confused by design. After all, you wonder, what are these ancient, alien creatures, growing in the secret dark? Hippocrates was supposedly using them to cauterize wounds around the 5th century B.C.E. In the Super Mario video games, mushrooms might give you extra lives; in HBO’s “The Last of Us,” they bring about the ruin of human civilization. © 2026 The New York Times Company

Keyword: Attention; Drug Abuse
Link ID: 30102 - Posted: 01.31.2026

By Andrew Jacobs In the billion-dollar race to commercialize psychedelic medicine, psilocybin, a naturally occurring hallucinogen better known as magic mushrooms, or “shrooms,” has decisively pulled ahead of the pack. The Food and Drug Administration in November said it would move up its review of a psilocybin treatment for severe depression by nine to 12 months, according to the applicant, Compass Pathways. It hopes to receive the agency’s approval for the therapy before the end of the year. The news is among the first concrete signs that the Trump administration is recognizing psychedelic medicine as a potential therapy tool. The moves have injected a fresh dose of optimism into a nascent field, which was rattled by the F.D.A.’s rejection in 2024 of MDMA-assisted therapy, the first psychedelic to reach a formal review by federal regulators. “Between research results and policy changes, it’s a watershed moment for psychedelic health care, and psilocybin is the star,” said Nate Howard, director of operations at InnerTrek, a psilocybin clinic in Portland, Ore. Mr. Howard was a driving force behind a successful ballot measure in 2023 that created Oregon’s psilocybin program. State lawmakers, however, are not waiting for regulators in the nation’s capital. Last year, New Mexico joined Colorado and Oregon in offering legal psilocybin therapy to adults. Lawmakers in a dozen states, including North Carolina, Maryland, Georgia and California, are considering easing restrictions on the drug using public funds to research the potential benefits of psilocybin therapy. © 2026 The New York Times Company

Keyword: Depression; Drug Abuse
Link ID: 30081 - Posted: 01.14.2026

Jon Hamilton Scientists are updating their view of how drugs like Adderall and Ritalin help children with attention deficit hyperactivity disorder stay on task. The latest evidence is a study of thousands of brain scans of adolescents that confirms earlier hints that stimulant drugs have little direct impact on brain networks that control attention. Instead, the drugs appear to activate networks involved in alertness and the anticipation of pleasure, scientists report in the journal Cell. "We think it's a combination of both arousal and reward, that kind of one-two punch, that really helps kids with ADHD when they take this medication," says Dr. Benjamin Kay, a pediatric neurologist at Washington University School of Medicine in St. Louis and the study's lead author. The results, along with those of smaller studies, support a "mindset shift about what stimulants are doing for people," says Peter Manza, a neuroscientist at the University of Maryland who was not involved in the research. The new research analyzed data from the Adolescent Brain Cognitive Development Study, a federally funded effort that includes brain scans of nearly 12,000 children. About 4% of these kids had ADHD when they entered the study, and nearly half of those were on a prescription stimulant. About 3.5 million children in the U.S. take an ADHD medication, and the number is rising. © 2025 npr

Keyword: ADHD; Learning & Memory
Link ID: 30059 - Posted: 12.31.2025

By Calli McMurray For the past two and a half years, a team of five labs in the San Francisco Bay Area have endeavored to nail down how psilocybin affects the way mice behave. Psilocybin and other psychedelic drugs have been shown to improve anxiety and depression symptoms in people, but results in mouse studies are less consistent. Those inconsistencies spell trouble for researchers trying to unpack the drug’s mechanism, because if behavioral changes in mice don’t mirror those in humans, the underlying biological changes might be irrelevant, says team member Boris Heifets, associate professor of anesthesiology, perioperative and pain medicine at Stanford University. So, to establish a behavioral ground truth, the five labs gave about 200 mice the same dose of psilocybin and measured how the drug affected the animals’ performance on a range of simple behavioral assays, including the elevated plus maze and open field, tail suspension and forced swim tests, while taking the drug as well as 24 hours later. While on psilocybin, the mice showed a temporary increase in anxiety-like behaviors, including spending less time than usual exploring new objects and open areas, the team reported in April. But, unlike in people, the drug had no lasting effects once it wore off. The issue, some behavioral neuroscientists argue, is not replication between labs—it’s the assays themselves. “I love the idea of these multisite experiments in animal models, but the models—the behavioral models—still have to be the right ones,” says Jennifer Mitchell, professor of neurology and psychiatry and behavioral sciences at the University of California, San Francisco. “The tests themselves—I’m not sure how much they tell us about what a psychedelic is actually doing.” © 2025 Simons Foundation

Keyword: Depression; Drug Abuse
Link ID: 30055 - Posted: 12.20.2025

By Jan Hoffman Around 2 a.m., Joseph felt the withdrawal coming on, sudden and hard. He fell to the floor convulsing, vomiting ferociously. The delirium and hallucinations were starting. He shook awake his friend, who had let him in earlier to shower, wash his clothes and grab some sleep. “Do you have a few dollars?” he pleaded. “I have to get right.” The friend, a community outreach worker who had been trying for years to get him into treatment, looked up at him standing over her raving and unfocused. “Either leave or let me call an ambulance,” she demanded. At 34, Joseph (who, with his friend, recounted the evening in interviews with The New York Times) had been through opioid withdrawals many times — on Philadelphia streets, in jail, in rehab. But he had never experienced anything as terrifyingly all-consuming as this. A new drug has been saturating the fentanyl supply in Philadelphia and moving to other cities throughout the East and Midwestern United States: medetomidine, a powerful veterinary sedative that causes almost instantaneous blackouts and, if not used every few hours, brings on life-threatening withdrawal symptoms. It has created a new type of drug crisis — one that is occasioned not by overdosing on the drug, but by withdrawing from it. Since the middle of last year, Philadelphia’s hospitals have been strained by patients coming in with what doctors have identified as medetomidine withdrawal. Although the heart rate slows drastically right after use, in withdrawal the opposite occurs: The heart rate and blood pressure become catastrophically high. Patients experience tremors and unstoppable vomiting. Many require intensive care. © 2025 The New York Times Company

Keyword: Drug Abuse
Link ID: 30053 - Posted: 12.17.2025

By Mattha Busby Bruce Damer had the audience under his Gandalf spell. He was giving a keynote speech in a grand hall at Breaking Convention, a psychedelic-consciousness conference in Exeter, England, in April 2025. Tall and slender, very much bearded, and sporting two large gold hoop earrings, one on either side, Damer looked exactly like you would expect a sexagenarian psychedelic professor to look. A boyishly enthusiastic speaker, he said a psychedelic trip had transported him through time to face a deep trauma. Nautilus Members enjoy an ad-free experience. Log in or Join now . “If you believe in a ‘mother ayahuasca’ or a healing force, I was allowed to experience my conception and birth and be in my mother’s belly,” Damer said. His birth mother had given him up because she and his father were too poor to raise him. Ayahuasca had released him from the pain. “Being in the belly, I could feel her love, and it healed,” he said. “As a result of the clarity and the opening of the blockage that had been this sort of knot in my belly, my whole system opened wide,” Damer continued. “And I thought for a moment, I could potentially travel through time to a place where I’ve been working on the question of how life began, the birth of us all.” In psychedelic science, a field dominated by scientists who are loath to be pigeon-holed as too woo-woo, Damer, 63, has become a cult figure by wearing his woo on his sleeve. His adoptive mother described him as “in his own world” when his new parents brought him home. And he has been his own thinker ever since. His science cred is sound: a Ph.D. in computer science from University College Dublin in Ireland, former relationships with Xerox and NASA, and papers published in journals like Astrobiology. Currently he is a research associate in the Department of Biomedical Engineering at the University of California, Santa Cruz. © 2025 NautilusNext Inc.,

Keyword: Depression; Drug Abuse
Link ID: 30052 - Posted: 12.17.2025

By Alex Kwan Despite decades of basic research, many neurological and psychiatric conditions lack effective treatments, or at least treatments that work for everyone. For that reason, when I talk with colleagues about the value of research, I often hear the same negative refrain: “Basic neuroscience has not produced new drugs.” Their argument carries some weight; many of today’s medications trace their origins to long-standing human use or to chance discoveries. The opium poppy, used for thousands of years to ease pain, paved the way for morphine and other opioids that are widely used as analgesics. Ketamine was designed as an anesthetic but was later unexpectedly revealed to be an antidepressant at low doses. Yet this narrative is incomplete. It overlooks a growing list of medications—including zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—that exist only because of insights from basic research. These drugs were not stumbled upon or borrowed from traditional remedies. They were born out of a long arc of studies in the lab. These success stories matter, because they demonstrate that neuroscience research can deliver new medicines. Acknowledging and publicizing such successes is especially important now, as public funding for basic research in the United States faces growing cuts and restrictions. The development of zuranolone stemmed from an observation about allopregnanolone, a steroid our bodies naturally produce. It has little interaction with steroid receptors and instead acts on GABA receptors in the brain, making neurons less excitable. In the late 1990s, researchers reported that allopregnanolone levels in the rat brain rise dramatically during pregnancy, reaching concentrations of up to three times higher than normal. Just before giving birth, however, the level drops precipitously. © 2025 Simons Foundation

Keyword: Depression; Pain & Touch
Link ID: 30051 - Posted: 12.17.2025

By Jan Hoffman To treat their pain, anxiety and sleep problems, millions of Americans turn to cannabis, which is now legal in 40 states for medical use. But a new review of 15 years of research concludes that the evidence of its benefits is often weak or inconclusive, and that nearly 30 percent of medical cannabis patients meet criteria for cannabis use disorder. “The evidence does not support the use of cannabis or cannabinoids at this point for most of the indications that folks are using it for,” said Dr. Michael Hsu, an addiction psychiatrist and clinical instructor at the University of California, Los Angeles, and the lead author of the review, which was published last month in the medical journal JAMA. (Cannabis refers to the entire plant; cannabinoids are its many compounds.) The analysis arrives amid a surging acceptance and normalization of cannabis products, a $32 billion industry. For the review, addiction experts at academic medical centers across the country studied more than 2,500 clinical trials, guidelines and surveys conducted mostly in the United States and Canada. They found a wide gulf between the health purposes for which the public seeks out cannabis and what gold-standard science shows about its effectiveness. The researchers distinguished between medical cannabis, sold at dispensaries, and pharmaceutical-grade cannabinoids — the handful of medicines approved by the Food and Drug Administration with formulations containing either low-grade THC, a psychoactive compound, or CBD, a nonintoxicating compound. Those medicines, including Marinol, Syndros and Cesamet, are available by prescription at conventional pharmacies and have had good results in easing chemotherapy-related nausea, stimulating the appetite of patients with debilitating illnesses like H.I.V./AIDS, and easing some pediatric seizure disorders. © 2025 The New York Times Company

Keyword: Drug Abuse; Pain & Touch
Link ID: 30045 - Posted: 12.13.2025